TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06402474

Intervention type: PROCEDURE
Intervention: sunbed position
Description: 30° reverse trendelenburg legs together 30° hip flexion (sunbed position)

Intervention type: PROCEDURE
Intervention: sunbed position
Description: 30° reverse trendelenburg legs together 30° hip flexion (sunbed position)
Study: NCT05698407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: loading dose of 0.45 microgram/ml dexmedetomidine plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml dexmedetomidine plus 0.07% ropivacaine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: loading dose of 0.45 microgram/ml sufentanil plus 0.09% ropivacaine, maintenance dose of 0.36 microgram/ml sufentanil plus 0.07% ropivacaine.
Study: NCT05369039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilust
Description: A selective phosphodiesterase 4 Inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Systemic corticosteroid
Study: NCT06016582

Intervention type: DEVICE
Group type: OTHER
Intervention: Use of virtual reality hypnosis headset during frozen embryo transfer
Description: The virtual reality hypnosis headset will be used before, during, and after the FET procedure:~* The headset will be put on 5 minutes prior to the procedure, allowing time for immersion in the virtual world.~* The headset will be kept on throughout the entire procedure (procedure duration less than 5 minutes).~* The headset will be worn for up to 5 minutes after the procedure. The patient will be free to choose her own auditory and visual scenario for the session.~Prior to the procedure and the device setup, the patient will be asked to complete a self-assessment anxiety questionnaire, the State-Trait Anxiety Inventory. This self-assessment questionnaire is a validated and standardized tool designed to measure temporary state anxiety related to a specific situation (in this case, the embryo transfer). After the procedure, the patient will need to complete the questionnaire again, along with another set of questions specifically designed for our study.
Study: NCT06322251

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of instrument to identify exposure to violence in close relationships
Description: Use of instrument to identify exposure to violence in close relationships

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of instrument to identify exposure to violence in close relationships
Description: Use of instrument to identify exposure to violence in close relationships

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Use of instrument to identify exposure to violence in close relationships
Description: Use of instrument to identify exposure to violence in close relationships
Study: NCT06026267

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20% High Dose Albumin
Description: A\]. Patients in the conventional albumin Arm will receive Human Albumin 20% 1.5 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 1 g/kg bodyweight (Maximum 100g)on day 3 along with standard medical therapy.~Duration of albumin over 24 hours.
Study: NCT00012727

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Matching Symptom Severity to Service Intensity
Study: NCT05782101

Intervention type: DIAGNOSTIC_TEST
Intervention: Integrated proteomic HPLC-ESI-MS analysis of salivary peptides
Description: A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Integrated proteomic HPLC-ESI-MS analysis of salivary peptides
Description: A targeted ESI mass spectrometry investigation, based on a top-down analysis of the intact salivary proteome will be performed.
Study: NCT06026267

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20% Reduced Dose Albumin
Description: B\]. Patients in the low dose albumin Arm will receive Human Albumin 20% 1.0 g/kg body weight (Maximum 100g) on day 1 after the diagnosis, followed by 0.5 g/kg bodyweight (Maximum 100g) on day 3 along with standard medical therapy.~Duration of albumin over 24 hours.
Study: NCT05212948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-268019-b
Description: Solution for IM injection
Study: NCT06113354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (MRace Implant and Delivery System)
Description: The MRace Implant is placed mitral valve posterior annulus using its delivery system via femoral vein access and a transeptal puncture~Other Names:~TMVr
Study: NCT05212948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-268019-b
Description: Solution for IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for IM injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline solution for IM injection
Study: NCT05217446

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Encorafenib
Description: capsule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: IV
Study: NCT04690283

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mimetic granules of Yiqi-Wenjing prescriptions
Description: The intervention relates to a multiple granules, which contains 2.5% concentrated Huangqi-Guizhi-Wuwu decoction (a classical traditional Chinese prescription consists of astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube), 2.5% concentrated Danggui-Sini decoction (a classical traditional Chinese prescription consists of angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root), bitter principle, food colouring and starch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huangqi-Guizhi-Wuwu granules
Description: The intervention relates to a traditional Chinese prescription granules, which contains astragalus membranaceus, cassia twig, radix paeoniae alba, ginger and jujube.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui-Sini granules
Description: The intervention relates to a traditional Chinese prescription granules, which contains angelica sinensis, cassia twig, radix paeoniae alba, asarum, tetrapanax papyriferus, jujube and honey-fried licorice root.
Study: NCT06165419

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT to the spine
Description: Stereotactic body radiation therapy (SBRT) administered to spine metastases
Study: NCT05503992

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention package
Description: The intervention package will include a mobile device configured with OpenSRP configured to facilitate clinical/service provision and stock management. The intervention also incorporates a training component on OpenSRP with accompanying follow-up supervisory visits for a limited period. Per the theory of changes, these activities will improve CHWs' knowledge and ability to use the platform for clinical care, dispensing, and workflow management, leading to an improved stock of commodities to meet preferred FP needs among last mile women.
Study: NCT00096850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
Study: NCT05217446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: IV
Study: NCT04702139

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: shoulder arthroplastis
Description: - Group (Treatment): Placement of the Game-Ready splint immediately after surgery for 12 hours. They will then be put on the standard splint which they will keep for 2 weeks as for the other group but without ice packs.
Study: NCT00096850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
Study: NCT06431776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: Molgramostim nebulizer solution will be administered once daily using a proprietary nebulizer optimized for the delivery of high molecular weight biologic compounds.
Study: NCT05352048

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Triggered Electromyography
Description: Triggered electromyography will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanomyography
Description: SENTIO MMG ball tip probe will be used during surgery to detect nerve impingement by pedicle screws used for spinal fusion. Threshold stimulation data from the device will be recorded, and the accuracy compared to the data from the triggered electromyography.
Study: NCT04702139

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: shoulder arthroplastis
Description: - Group (Control): Placement of a standard splint immediately after surgery for 2 weeks with ice packs to be used for an average of 8 days.
Study: NCT05883449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: anti-human CD30 × anti-human CD16A recombinant antibody therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-101
Description: NK cell therapy, intravenous infusion
Study: NCT05897138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
Description: Drug: Lenvatinib Capsules administered orally once daily~Drug: Tislelizumab 200 mg intravenous (IV) infusion administered on Day 1 of each cycle
Study: NCT04922125

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pulse flour
Description: Traditionally processed pulse flour in vitro digestion conditions were related to potentially influence appetite sensations.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Pre-processed pulse flour
Description: Pre-processing of pulse flour was related to altered in vitro digestion conditions and thus suggested to potentially influence appetite sensations.
Study: NCT04736511

Intervention type: OTHER
Group type: OTHER
Intervention: Star Excursion Balance Test
Description: The subject will be in unipodal support (only one foot on the ground) on the tested lower limb in the center of the platform. Three lines forming a Y will be arranged according to the lower limb in charge in three directions : anterior (ANT), posteromedial (PM) and posterolateral (PL). The goal is then to reach the longest distance possible in all three directions with the tip of the foot in relief before returning to the starting position. The subject will have 4 training trials per direction on each lower limb then 3 trials will be recorded in order to keep the average.

Intervention type: OTHER
Group type: OTHER
Intervention: Single leg Drop Vertical Jump
Description: The subject will drop from a step and land on one leg, then jump as high as possible and stabilize again on the same leg. The height of the step is 30 cm. The subject will perform 3 consecutive jumps in the strictest respect of the instructions: drop to the level of the mark on the ground and bounce as high as possible while spending a minimum of time on the ground. The subject must stabilize for 3 seconds during the second contact with the ground so that the instructions and measurements are reproducible.

Intervention type: OTHER
Group type: OTHER
Intervention: Unplanned sidestep cutting manoeuvre
Description: The objective is to create an unanticipated playing situation, close to the daily actions of the subjects in the practice of handball. The subject will make sidestep cutting manœuvre in front of an opponent simulated by a dummy used during usual training.~The subject will sprint in a straight line and then at the force platform will make a rapid change of direction on the side of his shooting arm or will continue his run in a straight line. A light signal randomly will indicate to the player the direction in which he must carry out his manoeuvre. A computer reconstruction of the kinematics and dynamics (knee moment) will be performed.
Study: NCT05883449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Lymphodepleting chemotherapy, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine, subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine, subcutaneously
Study: NCT04503291

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Metal stent placement
Description: Non-covered biliary metal stents are placed by endoscopy. The distal ends of metal stents are located above the major ampulla in the common bile duct or below the major ampulla in the duodenum.
Study: NCT05751616

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laminate veneers with speed sintering
Description: Zirconia specimens will be sintered using speed sintering cycle in a conventional furnace according to the manufacturer instructions.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laminate veneers with conventional sintering
Description: Zirconia specimens will be sintered using conventional sintering cycle in a conventional furnace according to the manufacturer instructions.
Study: NCT05821101

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Clareon Vivity and Clareon Vivity Toric IOLs targeted for mini-monovision with dominant eye set at emmetropia and non-dominant eye at -0.50.
Description: Bilateral implantation of IOLs such that dominant eye is corrected for distance vision while the non-dominant eye is corrected with a small amount of nearsightedness (-0.5 diopters).
Study: NCT04812080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EXPLORER PET/CT
Description: FDG PET Scans on the total body EXPLORER PET/CT scanner
Study: NCT05062278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Single-dose of intravenous vinblastine at 6mg/m2 (maximum 10mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea capsules
Description: Oral hydroxyurea at a dose of 50mg/kg/day until the administration of induction chemotherapy.
Study: NCT05883449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine, subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Immune cytokine, subcutaneously
Study: NCT05225012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Participants will then commence the intervention for the next 4 weeks. They will be sent the workbook via post. This will not be a standalone self-help intervention; participants will progress through the workbook alongside weekly emotional support sessions. These will either be over the phone or using an online video-call software, depending on participants preference. The first session will be an hour long to set-up the workbook, answer questions and go through goal setting. The following three weekly sessions will be half an hour to revisit exercises in the workbook, answer questions and review how the workbook progress is going. All sessions will be delivered by a trainee clinical psychologist who will receive standardised training and ongoing supervision from an experienced clinical psychologist.
Study: NCT05909709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte low dose
Description: Low dose containing 0.2 - 1.0 x 10\^11 particles and 3-10x10\^6 cell in 2mL which will be administered intra-facet into a single facet joint.~Preparation of low dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 2ml of the diluted product will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte medium dose
Description: Medium dose containing 0.6 - 3.0 x 10\^11 particles and 9-30x10\^6 cell in 6mL which will be administered intra-facet into three facet joints delivering 2ml/facet joint.~Preparation of medium dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, only 6ml of the diluted product will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alocyte high dose
Description: High dose containing 1.0 - 5.0 x 10\^11 particles and 15-50x10\^6 cell in 10mL which will be administered intra-facet into five facet joints delivering 2ml/facet joint.~Preparation of high dose: 1ml of Alocyte will be diluted with 9ml of saline. After mixing well, 10ml of diluted product will be used.
Study: NCT05267444

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Individualized motion-based interactive game program
Description: The participants will receive a 12-session, 4.5 months home visit service that is provided by the young adults, and supervised by an occupational therapist. Young adults will follow the individualized exercise plan with the older adults, facilitate their use of interactive games, provide psychological and technological support to help older adults cope with their fear of using technologies to perform physical activity.
Study: NCT06411392

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Antiarrhythmic Radiotherapy
Description: Patients with ventricular tachycardia will undergo cardiac stereotactic antiarrhythmic radiotherapy with a single fraction of 25 Gy to the arrhythmia substrate, as determined by electrophysiological cardiac mapping.
Study: NCT04880356

Intervention type: OTHER
Intervention: collection of data
Description: collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases

Intervention type: OTHER
Intervention: collection of data
Description: collection of retrospective and prospective data from adult patients with ultra-rare inherited neurological diseases
Study: NCT06286098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha lipoic acid
Description: THIOTACID 600 MG ORIGINAL ® Tablets manufactured by EVA PHARMA

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo identical Tablets are manufactured by EVA PHARMA containing the same excipients without Alpha Lipoic Acid.
Study: NCT06468969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Follow-up
Description: Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Follow-up
Description: Participants will receive comprehensive follow-up care starting from the 4th week post-surgery. Every 3 weeks, they will undergo a thorough assessment that includes:~Symptom Assessment Nutritional Assessment (using NRS 2002 and PG-SGA) Psychological Assessment (using DT, GAD-7, FCR-7, ISI, PHQ-9)
Study: NCT06423417

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifeHack
Description: See arm description
Study: NCT04914507

Intervention type: DEVICE
Group type: OTHER
Intervention: Anterior Vertebral Body Tethering
Description: Subject will receive anterior vertebral body tethering surgery.
Study: NCT04985370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education
Description: Three sessions of pain neuroscience education based on explaining patients: characteristics of acute versus chronic pain, function of acute pain, how acute pain is originated within the nervous system, how acute pain progress to chronic pain, and factors that contribute to central sensitization (e.g., emotions, stress, disease and pain beliefs, behaviors regarding pain...). All the explanations will be conducted using easy-understandable examples and metaphors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Progressive resistance exercise program based on isometric, concentric, eccentric, and pliometric contractions.